Delving into the Latest Updates on Beijing Jingda Biotechnology Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Jingda Bio is a company that specializes in creating genes and cell drugs, specifically NK and CAR-NK drugs. In addition to this, they offer a range of services to biopharmaceutical companies, including product development, medical research, and drug development.

Tags

Neoplasms

Hemic and Lymphatic Diseases

Immune System Diseases

CAR-NK

Biological products

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	7
Hemic and Lymphatic Diseases	4
Immune System Diseases	3

Top 5 Drug Type	Count

CAR-NK	7
Biological products	1

Top 5 Target	Count

CD19(B-lymphocyte antigen CD19)	2

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of JD010 in adult patients with relapsed or refractory B cell hematologic malignancies. JD010 injection is a CD19-targeted chimeric antigen receptor modified natural killer cells (CAR-NK) derived from a healthy donor

Start Date01 Dec 2022

Sponsor / Collaborator

Affiliated Hospital to Academy of Military Medical Sciences

[+1]

NCT05574608

/ Unknown statusEarly Phase 1IIT

Early Clinical Study of Allogenic CD123-CAR-NK Cells (JD023 Injection) in the Treatment of Refractory or Relapsed CD123-positive Acute Myeloid Leukemia

The CD123-Targeted CAR-NK cell therapy is a new treatment that is being investigated for treatment of acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety of CD123-CAR NK cells given to these patients.

Start Date01 Oct 2022

Sponsor / Collaborator

Affiliated Hospital to Academy of Military Medical Sciences

[+1]

CTR20255256

/ Not yet recruitingPhase 1

一项评估JD012-CEL注射液治疗晚期实体瘤安全性、耐受性的Ⅰ期临床研究

[Translation] A phase I clinical study evaluating the safety and tolerability of JD012-CEL injection for the treatment of advanced solid tumors.

主要目的：评价JD012-CEL注射液治疗晚期实体肿瘤的安全性、耐受性。次要目的：评价JD012-CEL注射液治疗晚期实体肿瘤的抗肿瘤初步有效性。探索性目的：探索JD012-CEL注射液的药代动力学特征；探索JD012-CEL注射液输注后生物标志物变化。

[Translation]

Primary Objective: To evaluate the safety and tolerability of JD012-CEL injection in the treatment of advanced solid tumors. Secondary Objective: To evaluate the preliminary antitumor efficacy of JD012-CEL injection in the treatment of advanced solid tumors. Exploratory Objectives: To explore the pharmacokinetic characteristics of JD012-CEL injection; to explore changes in biomarkers after infusion of JD012-CEL injection.

Start Date-

Sponsor / Collaborator

Beijing Jingda Biotechnology Co., Ltd.

[+1]

100 Clinical Results associated with Beijing Jingda Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Jingda Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Beijing Jingda Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Jingda Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Feb 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

4

2

Preclinical

Phase 1

2

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

JD010 ( CD19 )	B-Cell Malignant Neoplasm More	Phase 1
JD012-CEL	Advanced Malignant Solid Neoplasm More	Phase 1
JD001 ( CD19 )	Non-Hodgkin Lymphoma More	Preclinical
JDC06	Hematologic Neoplasms More	Preclinical
JD003	Multiple Myeloma More	Discovery